Early access to medicines in Spain: a retrospective hospital study with a proposal for a regulatory change
{{output}}
Background: Medicines awaiting price and reimbursement (P&R) decisions represent a delicate situation in the Spanish NHS. The interval between marketing authorisation (MA) and PR averages 616 days, leaving patients without standa... ...
